ERBB2 and breast cancer: More specifically, it was demonstrated that this antibody inhibits melanoma cell invasion and metastasis [11] as well as the interaction of surface HSP90 with the extracellular domain of ErbB-2, leading to impaired downstream signalling and subsequently reduced rate of in vitro breast cancer cell invasion [21].